A Phase I, open-label, dose-escalation study of DLL3/CD3 T-cell engager in patients with SCLC and other neuroendocrine neoplasms expressing DLL3 (NCT04429087)
AUC, area under the curve; CNS, central nervous system; DLL3, delta-like canonical Notch ligand 3; DLT, dose-limiting toxicity; ECOG PS, Eastern Cooperative Oncology Group performance status; IV, intravenous; LCNEC, large-cell neuroendocrine carcinoma; MTD, maximum tolerated dose; NEC, neuroendocrine carcinoma; OR, objective response; Q1W, every once a week; Q3W, every three weeks; SCC, squamous cell carcinoma; SCLC, small-cell lung cancer; RECIST, Response Evaluation Criteria In Solid Tumors.